CORZ Core Scientific, Inc. Common Stock

Core Scientific Inc. (NASDAQ: CORZ) is highly favored by analysts, with 12 out of 13 assigning Buy ratings and a median 1-year price target of $28.27, suggesting an 81.6% upside. The company, a bitcoin miner, is transitioning into AI-enabled data centers to diversify revenue streams due to crypto market volatility. This strategic move involves aggressive deals with large AI businesses to gain fast access to data centers.

PSquared Asset Management initiated a significant $7.28 million stake in Core Scientific during the third quarter of 2025, betting on its stabilizing digital infrastructure and potential merger with CoreWeave. However, the stock price faced a 30% decline after the merger agreement was terminated due to shareholder disapproval. Despite this setback, Core Scientific still possesses valuable power infrastructure and is shifting its focus towards hosting and AI-adjacent workloads.

PSquared Asset Management initiated a significant position in Core Scientific during the third quarter, which initially appeared to be a smart move due to the company's stabilizing digital infrastructure and potential merger. However, Core Scientific's stock price dropped by nearly 30% after the termination of its merger agreement with CoreWeave, raising questions about execution risk. Despite the stock plunge, the underlying operational shift towards hosting and compute services utilizing valuable power infrastructure remains.

This article analyzes Core Scientific Inc. Tranche 2 Warrants (CORZZ), highlighting a key finding of positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with AI-generated signals for support and resistance levels. The piece emphasizes an exceptional risk-reward short setup targeting a 21.3% downside versus 0.3% risk.

Voya Investment Management LLC reduced its stake in Core Scientific, Inc. (NASDAQ:CORZ) by 40.2% in the third quarter, holding 472,816 shares valued at $8.48 million. Despite this, analysts have a "Moderate Buy" consensus rating for Core Scientific with an average target price of $23.18, and director Eric Stanton Weiss recently increased his holdings. The company reported Q3 EPS of ($0.46), beating estimates, but revenue missed projections.

Analysts project a significant upside for Core Scientific Inc. (CORZ), with price targets suggesting over 69% growth despite a recent stock decline. The positive outlook is driven by the company's strong growth prospects in high-performance computing (HPC) and its strategic position to meet accelerating demand amidst power constraints. Core Scientific is expected to report improved financial results for Q4 2025, with a forecast of $108.48 million in revenue and a negative $0.14 GAAP EPS.